A US Food and Drug Administration advisory committee has, by a 7-3 vote, decided to recommend against the approval of GlaxoSmithKline's Ariflo (cilomilast) for the treatment of chronic obstructive pulmonary disease. The decision was based on concerns over the efficacy of the agent, as well as gastrointestinal side effects.
Analysts at Natexis Bleichroeder believe the panel's verdict will result in the FDA issuing either a not-approvable letter for the phosphodiesterase-4 inhibitor or asking for additional clinical data, thereby delaying approval by possibly one or two years. Ariflo was submitted for approval in December 2002, already one year behind schedule, note the analysts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze